AVITA Medical, Inc. (RCEL)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $16.50
- As of
Kresmion compiles this page from RCEL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AVITA Medical, Inc. (RCEL): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
See the full RCEL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RCEL on one page. Preview it with sample data, then open it live with a free account.
Preview the RCEL dossierActive events for RCEL
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 60% of RCEL (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 14.5%, EPS $-0.25 vs $-0.2924 estimate
- mediumEarnings below estimates
Q2-2025: Missed consensus by 50.2% - EPS $-0.38 vs $-0.253 estimate
- mediumEarnings below estimates
Missed consensus by 50.2% - EPS $-0.38 vs $-0.253 estimate
- mediumEarnings below estimates
Q3-2025: Missed consensus by 58.8% - EPS $-0.46 vs $-0.2897 estimate
FREE, NO ACCOUNT
Every event on RCEL, as it fires
You are seeing 5 of 7 events recorded on RCEL since 2026-06-03.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RCEL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 05380C102 · 2026Q2 | $88K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 05380C102 · 2026Q2 | $64K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RCEL
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
RCEL against its peers
RCEL's operating margin of -59.4% ranks in the 40th percentile of 23 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-06-30.
| Metric | RCEL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 71.6M USD | 100.0M USD | 31 | 23 |
| Gross margin | 82.1% | 65.1% | 85 | 22 |
| Operating margin | -59.4% | -25.5% | 40 | 23 |
| Net margin | -67.8% | -27.7% | 31 | 23 |
| Return on equity | n/a | -23.0% | n/a | 22 |
| P / E | n/a | 28.1x | n/a | 6 |
Peers (23): MASS, SSII, NPCE, DCTH, TCMD, OFIX, SENS, VMD, CV, KIDS, QSI, INMD, CLPT, TMCI, INFU, LAB, IART, QDEL, SIBN, TLSI, ELMD, BBNX, CBLL. Left out: BWAY (period gap), MOBI (no annual filing). Fiscal periods ending between 2025-12-28 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (RCEL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RCEL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RCEL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.